BioLight a publicly traded company on the Tel Aviv Stock Exchange, specializing in investments in biomed companies focusing on eye diseases, announced that its subsidiary, Diagnostear has entered into a binding LOI for a merger agreement with a Canadian corporation that is expected to list its shares on the Canadian Securities Exchange (CSE). Following the completion of the merger, Diagnostear is set to commence trading in Canada with an estimated value of US$ 33.5 million. BioLight will hold approximately 50% of the shares of the merged traded company, with the initial value of shares held by BioLIght being approximately US$ 16.8 million. As part of the agreement and a prerequisite for its closing, Diagnostear will raise approximately US$ 1 million, while the Canadian corporation will raise approximately US$ 2.5 million. Once the transaction is completed, and after all expenses related to the transaction and trading registration for the Canadian corporation have been paid, the merged company is expected to have a minimum cash balance of US$ 3 million. Diagnostear, of which Biolight currently holds 77% ownership, specializes in the development of eye tests based on tear fluid analysis. The funds raised from the aforementioned capital raises are designated to support the business plan of the merged company which includes advancing Diagnostear's dry eye detection product and the development of a new red-eye detection product. The completion of the transaction is subject to the aforementioned capital raisings and obtaining various customary necessary approvals. Yaacov Michlin, CEO of BioLight and Chairman of the Board of Directors of Diagnostear stated: "The merger and capital raise are expected to support Diagnostear in achieving its business objectives to commercialize the product for dry eye and complete the development of the red eye detection product. Both are parts of the company's strategy to become a global leader in diagnosing front-of-the-eye diseases through tear analysis in clinics. The registration for trading in Canada is expected to allow Diagnostear to increase awareness of its activities and effectively promote its plans."
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!